Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : F. Hoffmann-La Roche Ltd
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients with type 2 diabetes
To determine the doses of RO0730699 which, when compared to placebo, are efficacious, safe and tolerable in patients with type 2 diabetes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin
The primary objective is to determine the efficacy of taspoglutide on glycemic control (as assessed by HbA1c) in patients with type 2 diabetes mellitus inadequately controlled with metformin, compared...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer
To evaluate progression-free survival (PFS) in patients treated with carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO0728804 (dual PPAR alpha/gamma agonist) therapy when administered to patients with Type 2 diabetes mellitus
To determine the dose(s) of RO0728804 which are efficacious in improving glycemic control, safe and tolerable in patients with Type 2 diabetes when administered orally, once daily for 16 weeks as comp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Alectinib versus crizotinib in previously untreated patients with ALK-positive non-small cell lung cancer
Investigator assessed progression-free survival (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma
• To evaluate the efficacy of onartuzumab + bevacizumab relative to placebo + bevacizumab as measured by investigator-assessed progression-free survival (PFS) • To evaluate the efficacy of onartuzumab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A study investigating if RO5093151 is better than no treatment and if it causes side effects in patients who have glaucoma or high pressure in the eye
To assess the effect of RO5093151 on intraocular pressure.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancer Studie s Atezolizumabem a nab-Paklitaxelem u metastazujícího trojitě negativního karcinomu prsu
• to evaluate the efficacy of MPDL3280A + nab-paclitaxel compared with placebo + nab-paclitaxel as measured by progression-free survival (PFS; per investigator assessment using Response Evaluation Cr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin (trastuzumab) in patients with HER2-positive metastatic breast cancer Studio esplorativo, di fase II, a singolo braccio, multicentrico, per valutare l`efficacia e la sicurezza dell associazione di pertuzumab ed Herceptin (trastuzumab) in pazienti affette da carcinoma della mammella metastatico HER2-positivo
To make a preliminary assessment of the efficacy of pertuzumab in patients who have progressed during Herceptin-based therapy as determined by the objective response rate and/or the clinical benefit r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study of Atezolizumab in Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin plus placebo in Patients With Untreated Urothelial Carcinoma who are Ineligible for Cisplatin-Based Therapy
• To evaluate the efficacy of atezolizumab plus gemcitabine/carboplatin compared with placebo plus gemcitabine/carboplatin based on progression-free survival (PFS) and overall survival (OS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant